Literature DB >> 16451416

Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients.

C Peña1, C Gudiol, F Tubau, M Saballs, M Pujol, M A Dominguez, L Calatayud, J Ariza, F Gudiol.   

Abstract

Between 1996 and 2002, 103 hospitalised patients yielding one or more clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) were identified. A significant increase was observed in the incidence of ESBL-EC colonisation or infection during the study period (1.65 episodes/100 000 patient-days in 1996 to 12.6 episodes/100 000 patient-days in 2002; p 0.01). Infection developed in 70 (68%) patients (75 episodes), with surgical site (44%) and urinary tract (17%) infections being the most frequent. Pulsed-field gel electrophoresis showed extensive clonal diversity among the isolates. A case-control study and multivariate analysis identified female gender (OR 2.1; p 0.01), use of a nasogastric tube (OR 3.5; p 0.001) and previous antibiotic therapy (OR 3.9; p < 0.001) as independent variables associated with acquisition of ESBL-EC. The study demonstrated a progressive increase in the number of ESBL-EC isolates in a non-epidemic setting. Most cases of ESBL-EC colonisation or infection occurred in hospitalised patients exposed to invasive procedures and antibiotic pressure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16451416     DOI: 10.1111/j.1469-0691.2005.01358.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  25 in total

1.  Frequency of extended-spectrum β-lactamase (ESBL)-producing Gram-negative bacilli in a 200-bed multi-specialty hospital in Vellore district, Tamil Nadu, India.

Authors:  S Sankar; H Narayanan; S Kuppanan; B Nandagopal
Journal:  Infection       Date:  2012-04-25       Impact factor: 3.553

2.  Prospective study of fecal colonization by extended-spectrum-beta-lactamase-producing Escherichia coli in neutropenic patients with cancer.

Authors:  L Calatayud; M Arnan; J Liñares; M A Dominguez; C Gudiol; J Carratalà; M Batlle; J M Ribera; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

3.  Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies.

Authors:  M Arnan; C Gudiol; L Calatayud; J Liñares; M Á Dominguez; M Batlle; J M Ribera; J Carratalà; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-10-30       Impact factor: 3.267

4.  Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy.

Authors:  S Meier; R Weber; R Zbinden; C Ruef; B Hasse
Journal:  Infection       Date:  2011-06-25       Impact factor: 3.553

Review 5.  Managing urinary tract infections through phage therapy: a novel approach.

Authors:  Shikha Malik; Parveen Kaur Sidhu; J S Rana; Kiran Nehra
Journal:  Folia Microbiol (Praha)       Date:  2019-09-07       Impact factor: 2.099

6.  Risk factors for infection or colonization with CTX-M extended-spectrum-β-lactamase-positive Escherichia coli.

Authors:  Jennifer H Han; Kei Kasahara; Paul H Edelstein; Warren B Bilker; Ebbing Lautenbach
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

7.  Increasing rates of extended-spectrum B-lactamase-producing Escherichia coli and Klebsiella pneumoniae in uncomplicated and complicated acute pyelonephritis and evaluation of empirical treatments based on culture results.

Authors:  Bircan Kayaaslan; Zeynep Oktay; Imran Hasanoglu; Ayse Kaya Kalem; Fatma Eser; Muge Ayhan; Rahmet Guner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-01-03       Impact factor: 3.267

8.  Effect of ceftriaxone on the outcome of murine pyelonephritis caused by extended-spectrum-β-lactamase-producing Escherichia coli.

Authors:  A Tratselas; M Simitsopoulou; A Giannakopoulou; I Dori; S Saoulidis; K Kollios; P Papaioannidou; S Pournaras; E Roilides
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

9.  Risks factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care university hospital in Switzerland.

Authors:  S P Kuster; B Hasse; V Huebner; V Bansal; R Zbinden; C Ruef; B Ledergerber; R Weber
Journal:  Infection       Date:  2010-01-27       Impact factor: 3.553

10.  Pretransplant fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae and infection after liver transplant, France.

Authors:  Frédéric Bert; Béatrice Larroque; Catherine Paugam-Burtz; Federica Dondero; François Durand; Estelle Marcon; Jacques Belghiti; Richard Moreau; Marie-Hélène Nicolas-Chanoine
Journal:  Emerg Infect Dis       Date:  2012-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.